The treatment of immune-mediated skin diseases represents one of the most successful cases of translational immunology. Historically, therapies for these conditions relied on serendipitously discovered drugs or treatments, often yielding suboptimal efficacy and long-term toxicity.

With the advent of biologics, an increasing number of patients have achieved complete or near-complete clearance of skin lesions and itching. However, questions remain regarding the pharmacological mechanisms of biologics, their rational and safe application, long-term patient management, and early intervention strategies. To advance the fields of immune-mediated skin diseases, psoriasis, and urticaria—enhancing precision diagnosis and treatment, promoting appropriate and safe biologic use, and improving chronic disease management to alleviate patient burden—the "From Literature to Clinic: Psoriasis Comorbidity Management Symposium", hosted by the Chengdu Hi-Tech Zone Medical Association, was successfully held online on April 10, 2025.

This symposium bridged academic research and clinical practice, facilitating the translation of cutting-edge findings in psoriasis comorbidity management into real-world care. It empowered clinicians to improve early comorbidity recognition and standardized management while optimizing multidisciplinary collaboration. By enabling more precise risk-benefit assessments in treatment decisions, the event ultimately aims to enhance long-term patient outcomes, reduce disease burden, and advance from evidence-based medicine to personalized care.